AstraZeneca is still on target to submit data on its Covid-19 vaccine candidate to regulators before the end of the year, providing it can restart trials halted temporarily after a participant fell ill, the company’s chief executive has said.
阿斯利康(AstraZeneca)首席執行官表示,該公司總體進展順利,仍有望在年底前向監管機構提交有關其新型冠狀病毒肺炎(COVID-19,即2019冠狀病毒病)候選疫苗的數據——前提是該公司可以恢復在一名參與者患病后暫時中止的臨床試驗。
您已閱讀9%(361字),剩余91%(3485字)包含更多重要信息,訂閱以繼續探索完整內容,并享受更多專屬服務。